{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:44:01Z","timestamp":1791942241427,"version":"4.3.4"},"reference-count":39,"publisher":"The Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Malignant pheochromocytoma (PHEO) and paraganglioma (PGL) are rare and knowledge of the natural history is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We aimed to describe baseline characteristics and outcomes of patients with malignant PHEO and PGL (PPGL) and to identify predictors of shorter survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective review of patients with malignant PPGL evaluated from 1960 to 2016.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Referral center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>The group comprised 272 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures<\/jats:title>\n                    <jats:p>Baseline description, survival outcomes, and predictors of shorter survival were evaluated in patients with rapidly progressive (n = 29) and indolent disease (n = 188).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Malignant PPGL was diagnosed at a median age of 39 years (range, 7 to 83 years), with synchronous metastases in 96 (35%) patients. In 176 (65%) patients, metastases developed at a median of 5.5 years (range, 0.3 to 53.4 years) from the initial diagnosis. Median follow-up was 8.2 years (range, 0.01 to 54.1 years). Median overall and disease-specific survivals were 24.6 and 33.7 years, respectively. Shorter survival correlated with male sex (P = 0.014), older age at the time of primary tumor (P = 0.0011), synchronous metastases (P &amp;lt; 0.0001), larger primary tumor size (P = 0.0039), elevated dopamine (P = 0.0195), and not undergoing primary tumor resection (P &amp;lt; 0.0001). There was no difference in the type of primary tumor or presence of SDHB mutation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The clinical course of patients with malignant PPGL is remarkably variable. Rapid disease progression is associated with male sex, older age at diagnosis, synchronous metastases, larger tumor size, elevated dopamine, and not undergoing resection of primary tumor. An individualized approach to patients with metastatic PPGL is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jc.2017-00992","type":"journal-article","created":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T14:09:13Z","timestamp":1497276553000},"page":"3296-3305","source":"Crossref","is-referenced-by-count":282,"title":["Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years"],"prefix":"10.1210","volume":"102","author":[{"given":"Oksana","family":"Hamidi","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"William F","family":"Young","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M","family":"I\u00f1iguez-Ariza","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana Esi","family":"Kittah","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda","family":"Gruber","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Bancos","sequence":"additional","affiliation":[{"name":"Division of IT Services, Mayo Clinic, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrikant","family":"Tamhane","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Bancos","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2017,6,12]]},"reference":[{"issue":"12","key":"2020071623165103900_B1","first-page":"802","article-title":"Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979","volume":"58","author":"Beard","year":"1983","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2020071623165103900_B2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/MPA.0b013e3181ebb4f0","article-title":"The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer","volume":"39","author":"Chen","year":"2010","journal-title":"Pancreas"},{"issue":"34","key":"2020071623165103900_B3","doi-asserted-by":"crossref","first-page":"8812","DOI":"10.1200\/JCO.2005.03.1484","article-title":"Genetic testing in pheochromocytoma or functional paraganglioma","volume":"23","author":"Amar","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020071623165103900_B4","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11912-013-0320-x","article-title":"Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma","volume":"15","author":"Jimenez","year":"2013","journal-title":"Curr Oncol Rep"},{"key":"2020071623165103900_B5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000345671","article-title":"Novel hereditary forms of pheochromocytomas and paragangliomas","volume":"41","author":"Dahia","year":"2013","journal-title":"Front Horm Res"},{"issue":"5","key":"2020071623165103900_B6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1055\/s-0031-1301302","article-title":"An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes","volume":"44","author":"Gimenez-Roqueplo","year":"2012","journal-title":"Horm Metab Res"},{"issue":"7","key":"2020071623165103900_B7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ng.861","article-title":"Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma","volume":"43","author":"Comino-M\u00e9ndez","year":"2011","journal-title":"Nat Genet"},{"issue":"4","key":"2020071623165103900_B8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00109-012-0967-z","article-title":"A novel EPAS1\/HIF2A germline mutation in a congenital polycythemia with paraganglioma","volume":"91","author":"Lorenzo","year":"2013","journal-title":"J Mol Med (Berl)"},{"issue":"3","key":"2020071623165103900_B9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ng.533","article-title":"Germline mutations in TMEM127 confer susceptibility to pheochromocytoma","volume":"42","author":"Qin","year":"2010","journal-title":"Nat Genet"},{"issue":"9","key":"2020071623165103900_B10","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Castro-Vega","year":"2014","journal-title":"Hum Mol Genet"},{"key":"2020071623165103900_B11","volume-title":"Pathology and Genetics of Tumours of Endocrine Organs","author":"DeLellis"},{"issue":"3","key":"2020071623165103900_B12","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/ki.1991.244","article-title":"Pheochromocytoma: new concepts and future trends","volume":"40","author":"Bravo","year":"1991","journal-title":"Kidney Int"},{"issue":"5","key":"2020071623165103900_B13","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1161\/01.HYP.29.5.1133","article-title":"Tumor recurrence and hypertension persistence after successful pheochromocytoma operation","volume":"29","author":"Plouin","year":"1997","journal-title":"Hypertension"},{"issue":"6","key":"2020071623165103900_B14","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/00000658-199906000-00001","article-title":"Clinical experience over 48 years with pheochromocytoma","volume":"229","author":"Goldstein","year":"1999","journal-title":"Ann Surg"},{"issue":"6","key":"2020071623165103900_B15","first-page":"354","article-title":"Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series","volume":"56","author":"Sutton","year":"1981","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2020071623165103900_B16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/jpsu.2001.21612","article-title":"Pheochromocytoma in children","volume":"36","author":"Ciftci","year":"2001","journal-title":"J Pediatr Surg"},{"key":"2020071623165103900_B17","volume-title":"Pathology and Genetics of Tumours of Endocrine Organs","author":"DeLellis"},{"issue":"3","key":"2020071623165103900_B18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1373\/clinchem.2010.153320","article-title":"Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma","volume":"57","author":"Eisenhofer","year":"2011","journal-title":"Clin Chem"},{"key":"2020071623165103900_B19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1758-3284-2-23","article-title":"Malignant head and neck paragangliomas: is there an optimal treatment strategy?","volume":"2","author":"Moskovic","year":"2010","journal-title":"Head Neck Oncol"},{"issue":"6","key":"2020071623165103900_B20","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/jso.23297","article-title":"Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades","volume":"107","author":"Goffredo","year":"2013","journal-title":"J Surg Oncol"},{"issue":"3","key":"2020071623165103900_B21","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cncr.10252","article-title":"National Cancer Data Base report on malignant paragangliomas of the head and neck","volume":"94","author":"Lee","year":"2002","journal-title":"Cancer"},{"issue":"2","key":"2020071623165103900_B22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00423-011-0880-x","article-title":"Malignant pheochromocytomas and paragangliomas: a diagnostic challenge","volume":"397","author":"Gimm","year":"2012","journal-title":"Langenbecks Arch Surg"},{"issue":"3","key":"2020071623165103900_B23","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2020071623165103900_B24","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0090-4295(98)00612-8","article-title":"Pheochromocytomas: can malignant potential be predicted?","volume":"53","author":"John","year":"1999","journal-title":"Urology"},{"issue":"6","key":"2020071623165103900_B25","first-page":"245","article-title":"Prolonged survival in a patient with pulmonary metastases of a malignant pheochromocytoma","volume":"21","author":"van den Broek","year":"1978","journal-title":"Neth J Med"},{"issue":"10","key":"2020071623165103900_B26","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s004020100305","article-title":"Twenty-six-years\u2019 survival with multiple bone metastasis of malignant pheochromocytoma","volume":"121","author":"Yoshida","year":"2001","journal-title":"Arch Orthop Trauma Surg"},{"issue":"2","key":"2020071623165103900_B27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1210\/jc.2010-1588","article-title":"Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location","volume":"96","author":"Eisenhofer","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2020071623165103900_B28","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s002689900139","article-title":"Clinical spectrum and outcome of functional extraadrenal paraganglioma","volume":"20","author":"O\u2019Riordain","year":"1996","journal-title":"World J Surg"},{"issue":"12","key":"2020071623165103900_B29","doi-asserted-by":"crossref","first-page":"e0168413","DOI":"10.1371\/journal.pone.0168413","article-title":"Disentangling of malignancy from benign pheochromocytomas\/paragangliomas","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"2020071623165103900_B30","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer"},{"key":"2020071623165103900_B31","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1186\/1471-2407-14-523","article-title":"The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study","volume":"14","author":"Schovanek","year":"2014","journal-title":"BMC Cancer"},{"issue":"3","key":"2020071623165103900_B32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0002-9343(67)90275-6","article-title":"Dihydroxyphenylalanine secretion in a malignant pheochromocytoma","volume":"42","author":"Anton","year":"1967","journal-title":"Am J Med"},{"issue":"3","key":"2020071623165103900_B33","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1124\/jpet.103.049270","article-title":"Sources and significance of plasma levels of catechols and their metabolites in humans","volume":"305","author":"Goldstein","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"2020071623165103900_B34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.amjoto.2013.03.010","article-title":"Malignant head and neck paragangliomas: treatment efficacy and prognostic indicators","volume":"34","author":"Sethi","year":"2013","journal-title":"Am J Otolaryngol"},{"issue":"10","key":"2020071623165103900_B35","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"31","key":"2020071623165103900_B36","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1200\/JCO.2011.34.6353","article-title":"Metastatic pheochromocytoma\/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations","volume":"29","author":"King","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020071623165103900_B37","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.292.8.943","article-title":"Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations","volume":"292","author":"Neumann","year":"2004","journal-title":"JAMA"},{"issue":"11","key":"2020071623165103900_B38","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1210\/jc.2006-0423","article-title":"High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing","volume":"91","author":"Brouwers","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2020071623165103900_B39","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4158\/EP15725.OR","article-title":"Characteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma\/paraganglioma: an National Institutes of Health study","volume":"22","author":"Turkova","year":"2016","journal-title":"Endocr Pract"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/102\/9\/3296\/19703587\/jc.2017-00992.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/102\/9\/3296\/19703587\/jc.2017-00992.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T08:05:27Z","timestamp":1594973127000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/102\/9\/3296\/3866790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,12]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2017-00992","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,9,1]]},"published":{"date-parts":[[2017,6,12]]}}}